Wednesday, 21 August 2013

Diabetes and cancer – an AACE/ACE consensus statement

This document represents the official position of the American Association of Clinical Endocrinologists and the American College of Endocrinology

Empagliflozin As Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

Empagliflozin 10 and 25 mg for 24 weeks as add-on to metformin plus sulfonylurea improved glycemic control, weight, and systolic blood pressure and were well tolerated (Diabetes Care)

Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study

The observed 16.6% reduction in glycemia will prove clinically relevant if shown to translate to a similar reduction in both HbA1c concentrations and risk of diabetes-related complications in longer trials (PLoS ONE)

ABCD position statement on GLP-1 based therapies and pancreatic damage

We suggest that clinicians review patients on these therapies and ensure that the choice to start them over traditional therapies was based on sound therapeutic and patient centred goals, and that reasonable benefits have been achieved; this being a maxim that can be applied to any newer treatment (ABCD)

No comments:

Post a Comment